Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)
Primary Purpose
Metastatic Renal Cell Carcinoma
Status
Completed
Phase
Phase 2
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Sunitinib 2/1
Sunitinib 4/2
Sponsored by
About this trial
This is an interventional treatment trial for Metastatic Renal Cell Carcinoma focused on measuring Renal cell carcinoma, Sunitinib, phase II study, Randomized study
Eligibility Criteria
Inclusion Criteria:
- Histologically or cytologically confirmation of renal cell carcinoma with a clear cell histologic component
- Patients must present with stage IV disease not amenable to surgery, radiotherapy, or combined modality therapy with curative intent.
- Measurable disease according to RECIST criteria are required but patients with evaluable lesions without measurable lesions are allowed to be enrolled to this study
- ECOG performance status 2 or better
- Age 18 years or older
- Adequate bone marrow, hepatic, and renal function
- Life expectancy of > 3 months
- Singed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment
Exclusion Criteria:
- Known spinal cord compression or carcinomatous meningitis
- Diagnosis of any serious secondary malignancy within the last 2 years, except for adequately treated basal cell or squamous cell carcinoma of skin, or in situ carcinoma of cervix uteri
- Hypertension that cannot be controlled by medications (blood pressure > 150/90 mmHg despite optimal medical therapy)
- Treatment with anticonvulsant agents and treatment with therapeutic doses of coumadin currently or within 2 weeks prior to first day of sunitinib administration. Low dose coumadin for DVT prophylaxis is permitted (up to 2 mg/day).
- Pregnancy or breast feeding.
- Other severe acute or chronic medical or psychiatric condition
- Prior treatment on sunitinib, sorafenib, or bevacizumab.
Sites / Locations
- Daegu Catholic University Hospital
- Yeungnam University Medical Center
- Asan Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Sunitinib 4/2
Sunitinib 2/1
Arm Description
Sunitinib 50 mg PO 4-week on and 2-week off
Sunitinib 50 mg PO 2-week on 1-week off
Outcomes
Primary Outcome Measures
Treatment failure rate (progressive disease, treatment withdrawal due to unacceptable toxicities, or any death)
From the date of randomization to the date of progressive disease, treatment withdrawal, or death from any cause, which came first.
Secondary Outcome Measures
Overall response rate
RECIST v.1.1 will be used to assess tumor responses
quality of life
EORTC QLQ C30 and EQ5D will be used to assess the quality of life
Progression free survival
Overall survival
Adverse events
CTC AE v.3.0
Full Information
NCT ID
NCT00570882
First Posted
December 10, 2007
Last Updated
September 22, 2014
Sponsor
Asan Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00570882
Brief Title
Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)
Official Title
A Randomized Phase II Trial Of Sunitinib Administered Daily For 4 Weeks, Followed By 2-Week Rest Vs. 2-Week On And 1-Week Off In Metastatic Renal Cell Carcinoma
Study Type
Interventional
2. Study Status
Record Verification Date
September 2014
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
June 2014 (Actual)
Study Completion Date
June 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Asan Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is to evaluate the efficacy, safety, and feasibility of sunitinib in 4/2 and 2/1 regimen in previously untreated metastatic RCC to select the most promising regimen, which should be used in further studies of this patient population.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metastatic Renal Cell Carcinoma
Keywords
Renal cell carcinoma, Sunitinib, phase II study, Randomized study
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
76 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sunitinib 4/2
Arm Type
Active Comparator
Arm Description
Sunitinib 50 mg PO 4-week on and 2-week off
Arm Title
Sunitinib 2/1
Arm Type
Experimental
Arm Description
Sunitinib 50 mg PO 2-week on 1-week off
Intervention Type
Drug
Intervention Name(s)
Sunitinib 2/1
Intervention Description
Sunitinib 50 mg PO 2 weeks followed by 1 week rest
Intervention Type
Drug
Intervention Name(s)
Sunitinib 4/2
Intervention Description
Sunitinib 50 mg PO 4 weeks followed by 2 week rest
Primary Outcome Measure Information:
Title
Treatment failure rate (progressive disease, treatment withdrawal due to unacceptable toxicities, or any death)
Description
From the date of randomization to the date of progressive disease, treatment withdrawal, or death from any cause, which came first.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Overall response rate
Description
RECIST v.1.1 will be used to assess tumor responses
Time Frame
6 months
Title
quality of life
Description
EORTC QLQ C30 and EQ5D will be used to assess the quality of life
Time Frame
12 months
Title
Progression free survival
Time Frame
12 months
Title
Overall survival
Time Frame
36 months
Title
Adverse events
Description
CTC AE v.3.0
Time Frame
about 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically or cytologically confirmation of renal cell carcinoma with a clear cell histologic component
Patients must present with stage IV disease not amenable to surgery, radiotherapy, or combined modality therapy with curative intent.
Measurable disease according to RECIST criteria are required but patients with evaluable lesions without measurable lesions are allowed to be enrolled to this study
ECOG performance status 2 or better
Age 18 years or older
Adequate bone marrow, hepatic, and renal function
Life expectancy of > 3 months
Singed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment
Exclusion Criteria:
Known spinal cord compression or carcinomatous meningitis
Diagnosis of any serious secondary malignancy within the last 2 years, except for adequately treated basal cell or squamous cell carcinoma of skin, or in situ carcinoma of cervix uteri
Hypertension that cannot be controlled by medications (blood pressure > 150/90 mmHg despite optimal medical therapy)
Treatment with anticonvulsant agents and treatment with therapeutic doses of coumadin currently or within 2 weeks prior to first day of sunitinib administration. Low dose coumadin for DVT prophylaxis is permitted (up to 2 mg/day).
Pregnancy or breast feeding.
Other severe acute or chronic medical or psychiatric condition
Prior treatment on sunitinib, sorafenib, or bevacizumab.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jae-Lyun Lee, MD, PhD
Organizational Affiliation
Asan Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Daegu Catholic University Hospital
City
Daegu
Country
Korea, Republic of
Facility Name
Yeungnam University Medical Center
City
Daegu
Country
Korea, Republic of
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
138-736
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
26347107
Citation
Lee JL, Kim MK, Park I, Ahn JH, Lee DH, Ryoo HM, Song C, Hong B, Hong JH, Ahn H. RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann Oncol. 2015 Nov;26(11):2300-5. doi: 10.1093/annonc/mdv357. Epub 2015 Sep 7.
Results Reference
derived
Learn more about this trial
Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)
We'll reach out to this number within 24 hrs